Weekly News Round-up – 12/3/21


In the news this week,real-world data has found the Pfizer vaccine to have high effectiveness against asymptomatic COVID-19. In other news, the EMA has advised continued use of AstraZeneca’s vaccine despite blood clot scares, and Zolgensma is set to be available on the NHS in England for the first time.
EU COUNTRIES SUSPEND AZ VACCINE OVER BLOOD CLOTS – The EMA has declared the AZ/Oxford University COVID-19 vaccine can continue production as they begin an investigation into possible blood clots caused by the product. 30 cases have so far been reported, with several countries suspending inoculations at the time. AZ noted the vaccine had been extensively studied in human trials, and were subject to rigorous quality controls.
PFIZER VACCINE GIVES HIGH PROTECTION AGAINST COVID-19, STUDY FINDS – Real-world data from Israel suggests the Pfizer/BioNTech vaccine grants high protection against asymptomatic COVID-19. The as-yet un-peer reviewed study found the vaccine is 97% effective against disease and death, and 94% effective against infection without symptoms. The data does not specify how effective the vaccine is yet against South African and Brazilian variants, however.
NHS TO STOCK MOST EXPENSIVE DRUG IN THE WORLD FOR FIRST TIME – Zolgensma, the most expensive drug in the world, is to be made available on the NHS in England for the first time later in 2021. The drug, designed to halt progression of spinal muscular atrophy, would benefit around 80 infants a year in England. This is the most expensive treatment yet approved by the National Institute for Health and Care Excellence.
In other news:
R&D
Takeda buys Maverick Therapeutics for $525 million
Clinical
Bluebird Bio hoping to restart LentiGlobin trials after cancer scare
Manufacturing
Rollout of US COVID vaccine complicated by J&J manufacturing difficulties
Roche withdraws US bladder cancer indication for Tecentriq
That’s all for now. See you next week!
Joshua Neil, Editor
Proventa International

The Opportunities and Challenges of CNS Drug Delivery: An Interview with Marcie Glicksman, Enclear Therapies
Developing therapeutics that treat diseases of the brain especially has been an uphill struggle in terms of optimising drug delivery systems. While some pharma companies attempt to overcome hurdles like the blood-brain barrier, others are looking beyond this strategy to...
2 years agoThe Opportunities and Challenges of CNS Drug Delivery: An Interview with Marcie Glicksman, Enclear Therapies
Developing therapeutics that treat diseases of the brain especially has been an uphill struggle in terms of optimising drug delivery systems. While some pharma companies attempt to overcome hurdles like the blood-brain barrier, others are looking beyond this strategy to...
2 years ago
RNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years agoRNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years ago
Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years agoRaising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years ago